Table 2.

Clinicopathologic characteristics of surrogate TGCA molecular groups. Values are counts (percentages) or mean ± standard deviation [interquartile range].

Clinicopathologic Characteristics	POLE	MMRd	p53abn	NSMP	p-Value
	(n = 9; 7.2%)	(n = 41; 32.8%)	(n = 26; 20.8%)	(n = 49; 39.2%)
Age, years	61.2 ± 13.9	64.2 ± 10.0	65.0 ± 10.0	60.6 ± 11.0	0.266
	[52–71]	[57–73]	[59–74]	[55–69]
Body mass index, kg/m2	25.3 ± 4.6	26.8 ± 6.1	25.4 ± 4.1	29.5 ± 7.8	0.104
	[21.3–28.1]	[22.7–28.2]	[22.8–27.2]	[24.0–33.8]
Tumor type					<0.001
Endometrioid	8 (88.9)	30 (73.2)	7 (26.9)	45 (91.8)
Dedifferentiated/ Undifferentiated	1 (11.1)	11 (26.8)	1 (3.8)	4 (8.2)
Serous	0 (0.0)	0 (0.0)	15 (57.7)	0 (0.0)
Clear cell	0 (0.0)	0 (0.0)	3 (11.5)	0 (0.0)
Heterogeneity	4 (44.4)	21 (51.2)	10 (38.5)	14 (28.6)	0.168
Grade					<0.001
1	2 (22.2)	11 (26.8)	1 (3.8)	22 (44.9)
2	3 (33.3)	14 (34.1)	0 (0.0)	18 (36.7)
3	4 (44.4)	16 (39.0)	25 (96.2)	9 (18.4)
Depth of invasion ≥50%	1 (11.1)	15 (36.6)	9 (34.6)	10 (20.4)	0.208
LVSI	2 (22.2)	14 (34.1)	11 (42.3)	10 (20.4)	0.196
Lymph node status					0.141
Negative	8 (88.9)	31 (75.6)	15 (57.7)	41 (83.7)
Positive	1 (11.1)	8 (19.5)	10 (38.5)	5 (10.2)
FIGO stage					0.011
IA	5 (55.6)	19 (46.3)	12 (46.2)	35 (71.4)
IB/II	2 (22.2)	12 (29.3)	1 (3.8)	7 (14.3)
III	2 (22.2)	9 (22.0)	12 (46.2)	7 (14.3)
IV	0 (0.0)	1 (2.4)	1 (3.8)	0 (0.0)
Extensive necrosis	6 (66.7)	23 (56.1)	11 (42.3)	19 (38.8)	0.235
MELF	5 (55.6)	24 (58.5)	3 (11.5)	14 (28.6)	<0.001
Tumor budding	7 (77.8)	23 (56.1)	8 (30.8)	14 (28.6)	0.004
High sTILs	9 (100.0)	35 (85.4)	19 (73.1)	26 (53.1)	0.001
High iTILs	9 (100.0)	37 (90.2)	17 (65.4)	23 (46.9)	<0.001
Mitoses/10 HPF	78.1 ± 34.5	55.3 ± 23.7	86.3 ± 43.7	33.3 ± 27.7	<0.001
	[50–103]	[40–70]	[45–130]	[10–42]
Ki67 proliferative index	58.5 ± 14.9	57.9 ± 14.9	56.0 ± 16.7	36.6 ± 18.3	<0.001
	[55.1–68.2]	[47.1–69.6]	[49.3–69.7]	[23.3–50.0]